Liver transplantation and transthyretin amyloidosis

Muscle and Nerve

Volumn 47, Issue 2, 2013, Pages 157-162

  Benson, Merrill D ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Richard L Roudebush Veterans Affair Medical Center   (United States)

Author keywords

Amyloidosis; Familial amyloidotic polyneuropathy; FAP; Liver transplant; Transthyretin; TTR

Indexed keywords

PREALBUMIN;

AMYLOIDOSIS; AUTOSOMAL DOMINANT DISORDER; FAMILIAL AMYLOID POLYNEUROPATHY; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GENETIC VARIABILITY; HEART AMYLOIDOSIS; HEART TRANSPLANTATION; HUMAN; LIVER FAILURE; LIVER TRANSPLANTATION; LONG TERM SURVIVAL; PRIORITY JOURNAL; REVIEW; TRANSTHYRETIN AMYLOIDOSIS;

AMYLOID NEUROPATHIES, FAMILIAL; DISEASE PROGRESSION; HUMANS; LIVER TRANSPLANTATION; TREATMENT OUTCOME;

EID: 84873028718     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.23521     Document Type: Review

References (49)

1. Holmgren G, Steen L, Ekstedt J, Groth C-G, Ericzon B-G, Eriksson S, et al. Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet 1991; 40: 242-246.
2. Holmgren G, Ericzon B-G, Groth C-G, Steen L, Suhr O, Andersen O, et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 1993; 341: 1113-1116.
3. Benson MD. Amyloidosis and other protein deposition diseases. In: Rimoin DL, Connor JM, Pyeritz RE, Korf BR, editors. Emery and Rimoin's principles and practice of medical genetics, 5th ed. Vol. 2. New York: Churchill Livingstone; 2005. p 1821-1834.
4. Wallace MR, Naylor SL, Kluve-Beckerman B, Long GL, McDonald L, Shows TB, et al. Localization of the human prealbumin gene to chromosome 18. Biochem Biophys Res Commun 1985; 129: 753-758.
5. Hamilton JA, Benson MD. Transthyretin. A review from a structural perspective. Cell Mol Life Sci 2001; 58: 1491-1521.
6. Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 2007; 36: 411-223.
7. Andrade C. A peculiar form of peripheral neuropathy. Familial atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 1952; 75: 408-427.
8. Goren H, Steinberg MC, Farboody GH. Familial oculoleptomeningeal amyloidosis. Brain 1980; 103: 473-495.
9. Westermark P, Sletten K, Johansson B, Cornwell GG. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci USA 1990; 87: 2843-2845.
10. Robbins J. Thyroxine-binding proteins. Prog Clin Biol Res 1976; 5: 331-355.
11. Benson MD, Kluve-Beckerman B, Liepnieks JJ, Murrell JR, Hanes D, Uemichi T. Metabolism of amyloid proteins. In: Bock GR, Goode JA, editors. The nature and origin of amyloid fibrils: Ciba Foundation Symposium 199. New York: John Wiley & Sons; 1996. p 104-118.
12. Shakespeare, Hamlet Prince of Denmark. Act IV, scene 1.
13. Suhr OB, Holmgren G, Steen L, Wikström L, Norden G, Friman S, et al. Liver transplantation in familial amyloidotic polyneuropathy. Follow-up of the first 20 Swedish patients. Transplantation 1995; 60: 933-938.
14. de Carvalho M, Conceição I, Bentes C, Luís ML. Long-term quantitative evaluation of liver transplantation in familial amyloid polyneuropathy (Portuguese V30M). Amyloid 2002; 9: 126-133.
15. Tashima K, Ando Y, Terazaki H, Yoshimatsu S, Suhr OB, Obayashi K, et al. Outcome of liver transplantation for transthyretin amyloidosis: follow-up of Japanese familial amyloidotic polyneuropathy patients. J Neurol Sci 1999; 171: 19-23.
16. Adams D, Samuel D, Goulon-Goeau C, Nakazato M, Costa PM, Feray C, et al. The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation. Brain 2000; 123: 1495-1504.
17. Yamashita T, Ando Y, Okamoto S, Misumi Y, Hirahara T, Ueda M, et al. Long-term survival after liver transplantation in patients with familial amyloid polyneuropathy. Neurology 2012; 78: 637-643.
18. Jonsén E, Suhr OB, Tashima K, Athlin E. Early liver transplantation is essential for familial amyloidotic polyneuropathy patients' quality of life. Amyloid 2001; 8: 52-57.
19. Suhr OB, Friman S, Ericzon BG. Early liver transplantation improves familial amyloidotic polyneuropathy patients' survival. Amyloid 2005; 12: 233-238.
20. Bergethon PR, Sabin TD, Lewis D, Simms RW, Cohen AS, Skinner M. Improvement in the polyneuropathy associated with familial amyloid polyneuropathy after liver transplantation. Neurology 1996; 47: 944-951.
21. Bittencourt PL, Couto CA, Farias AQ, Marchiori P, Bosco Massarollo PC, Mies S. Results of liver transplantation for familial amyloid polyneuropathy type I in Brazil. Liver Transpl 2002; 8: 34-39.
22. Ikeda S, Takei Y, Yanagisawa N, Matsunami H, Hashikura Y, Ikegami T, et al. Peripheral nerves regenerated in familial amyloid polyneuropathy after liver transplantation. Ann Intern Med 1997; 127: 618-620.
23. Jonsén E, Suhr OB, Athlin E, Wikström L. Quality of life after liver transplantation in patients with familial amyloidotic polyneuropathy. Amyloid 1996; 3: 124-129.
24. Steen L, Holmgren G, Suhr O, Wikström L, Groth C-G, Ericzon B-G. World-wide survey of liver transplantation in patients with familial amyloidotic polyneuropathy. Amyloid 1994; 1: 138-142.
25. Dubrey SW, Davidoff R, Skinner M, Bergethon P, Lewis D, Falk RH. Progression of ventricular wall thickening after liver transplantation for familial amyloidosis. Transplantation 1997; 64: 74-80.
26. Olofsson BO, Backman C, Karp K, Suhr OB. Progression of cardiomyopathy after liver transplantation in patients with familial amyloidotic polyneuropathy, Portuguese type. Transplantation 2002; 73: 745-751.
27. Stangou AJ, Hawkins PN, Heaton ND, Rela M, Monaghan M, Nihoyannopoulos P, et al. Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy: implications for amyloid fibrillogenesis. Transplantation 1998; 66: 229-233.
28. Delahaye N, Rouzet F, Sarda L, Tamas C, Dinanian S, Plante-Bordeneuve V. Impact of liver transplantation on cardiac autonomic denervation in familial amyloid polyneuropathy. Medicine 2006; 85: 229-238.
29. Hörnsten R, Wiklund U, Olofsson B-O, Jensen SM, Suhr OB. Liver transplantation does not prevent the development of life-threatening arrhythmia in familial amyloidotic polyneuropathy, Portuguese-type (ATTR Val30Met) patients. Transplantation 2004; 78: 112-116.
30. Munar-Qués M, Salva-Ladaria L, Mulet-Perera P, Solé M, López-Andreu FR, Saraiva MJ. Vitreous amyloidosis after liver transplantation in patients with familial amyloid polyneuropathy: ocular synthesis of mutant transthyretin. Amyloid 2000; 7: 266-269.
31. Blevins G, Macaulay R, Harder S, Fladeland D, Yamashita T, Yazaki M, et al. Oculoleptomeningeal amyloidosis in a large kindred with a new transthyretin variant Tyr69His. Neurology 2003; 60: 1625-1630.
32. Yazaki M, Mitsuhashi S, Tokuda T, Kametani F, Takei YI, Koyama J, et al. Progressive wild-type transthyretin deposition after liver transplantation preferentially occurs onto myocardium in FAP patients. Am J Transplant 2007; 7: 235-242.
33. Liepnieks JJ, Benson MD. Progression of cardiac amyloid deposition in hereditary transthyretin amyloidosis patients after liver transplantation. Amyloid 2007; 14: 277-282.
34. Nardo B, Beltempo P, Bertelli R, Montalti R, Vivarelli M, Cescon M, et al. Combined heart and liver transplantation in four adults with familial amyloidosis: experience of a single center. Transplant Proc 2004; 36: 645-647.
35. Pilato E, Dell'Amore A, Botta L, Arpesella G. Combined heart and liver transplantation for familial amyloidotic neuropathy. Eur J Cardiothorac Surg 2007; 32: 180-182.
36. Barreiros AP, Post F, Hoppe-Lotichius M, Linke RP, Vahl CF, Schäfers HJ, et al. Liver transplantation and combined liver-heart transplantation in patients with familial amyloid polyneuropathy: a single-center experience. Liver Transpl 2010; 16: 314-323.
37. Liepnieks JJ, Zhang LQ, Benson MD. Progression of transthyretin amyloid neuropathy after liver transplantation. Neurology 2010; 75: 324-327.
38. Furtado A, Tomé L, Oliveira FJ, Furtado E, Viana J, Perdigoto R. Sequential liver transplantation. Transplant Proc 1997; 29: 467-468.
39. Matsunami H, Makuuchi M, Kawasaki S, Hashikura Y, Ikegami T, Nakazawa Y, et al. A case of familial amyloid polyneuropathy treated with partial liver transplantation using a graft from a living related donor. Transplantation 1995; 60: 301-303.
40. Nishizaki T, Kishikawa K, Yoshizumi T, Uchiyama H, Okano S, Ikegami T, et al. Domino liver transplantation from a living related donor. Transplantation 2000; 70: 1236-1239.
41. Ikeda S, Takei Y, Yanagisawa N, Matsunami H, Hashikura Y, Ikegami T, et al. Partial liver transplantation from living donors in familial amyloid polyneuropathy. Amyloid 1997; 4: 18-23.
42. Stangou AJ, Heaton ND, Hawkins PN. Transmission of systemic transthyretin amyloidosis by means of domino liver transplantation. N Engl J Med 2005; 352: 2356.
43. Sousa MM, Ferrão J, Fernandes R, Guimarães A, Geraldes JB, Perdigoto R, et al. Deposition and passage of transthyretin through the blood-nerve barrier in recipients of familial amyloid polyneuropathy livers. Lab Invest 2004; 84: 865-873.
44. Takei Y, Gono T, Yazaki M, Ikeda S, Ikegami T, Hashikura Y, et al. Transthyretin-derived amyloid deposition on the gastric mucosa in domino recipients of familial amyloid polyneuropathy liver. Liver Transpl 2007; 13: 215-218.
45. Suhr O, Danielsson A, Holmgren G, Steen L. Malnutrition and gastrointestinal dysfunction as prognostic factors for survival in familial amyloidotic polyneuropathy. J Intern Med 1994; 235: 479-485.
46. Johnson SM, Wiseman RL, Sekijima Y, Green NS, Adamski-Werner SL, Kelly JW. Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. Acc Chem Res 2005; 38: 911-921.
47. Coelho T, Maia L, Martins da Silva A, Waddington-Cruz M, Planté-Bordeneuve V, Lozeron P, et al. Tafamidis (Fx-1006A): a first-in-class disease-modifying therapy for transthyretinfamilial amyloid. Amyloid 2010; 17: 75-76.
48. Tanaka K, Yamada T, Ohyagi Y, Asahara H, Horiuchi I, Kira J. Suppression of transthyretin expression by ribozymes: a possible therapy for familial amyloidotic polyneuropathy. J Neurol Sci 2001; 183: 79-84.
49. Benson MD, Kluve-Beckerman B, Zeldenrust SR, Siesky AM, Bodenmiller DM, Showalter AD. Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve 2006; 33: 609-618.